Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for copd
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
pulmonarydisease (COPD) are chronic, progressive, and ultimately fatal, diseases of the lungs. Emphysema is one of two conditions that are classed as COPD, the other being chronic bronchitis. Emphysema can exist without chronic bronchitis as a distinct respiratory condition. Patients with COPD can have predominantly emphysema, predominantly chronic bronchitis, or both. Chronicobstructivepulmonarydisease is the second most common lungdisease in the UK. Treatments for emphysema/COPD include lifestyle (...) Apr 23]; Available from: https://www.mayoclinic.org/diseases-conditions/pneumothorax/symptoms-causes/syc- 20350367. 4. British Lung Foundation. COPD (chronicobstructivepulmonarydisease): emphysema. 2020 [cited 2020 Apr 23]; Available from: https://www.blf.org.uk/support-for- you/copd/emphysema. 5. Cetti EJ, Moore AJ, Geddes DM. Collateral ventilation. Thorax. 2006;61(5):371-3. 6. MedlinePlus. Subcutaneous emphysema. 2020 [cited 2020 May 07]; Available from: https://medlineplus.gov/ency/article
The Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China. PMID: 32907384 DOI: Item in Clipboard Full-text links Cite Display options Display options Format Abstract Objective: To investigate the effects of a mobile health smartphone application to support self-management programmes on quality of life, self-management behaviour and exercise and smoking cessation behaviour in patients with chronicobstructivepulmonarydisease (COPD). Design: A randomised controlled, single-blind (...) participants' exercise and smoking cessation behaviour. Conclusions: The mobile health smartphone application to support self-management programmes was effective in improving health-related quality of life and self-management behaviour in patients with COPD. Trial registration: This study was registered in Chinese clinicaltrials.gov. Keywords: Chronicobstructivepulmonarydisease; mobile health application; randomised control trial; self-management. Similar articles McCabe C, McCann M, Brady AM. McCabe C
rehabilitation for patients with COPD: a randomised controlled trial , , , , , , , , , , , Affiliations Expand Affiliations 1 Laboratory of RespiratoryDiseases and Thoracic Surgery (BREATHE), Department of ChronicDiseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium. 2 University Pitágoras UNOPAR, Department of Rehabilitation Sciences, Londrina, Brazil. 3 Both authors contributed equally. 4 Monash University, Department of Physiotherapy, Victoria, Australia. 5 Monash Health, Monash Lung (...) , Belgium email@example.com. PMID: 32444407 DOI: Item in Clipboard Full-text links Cite Display options Display options Format Abstract The development of contractile muscle fatigue (CMF) affects training responses in patients with chronicobstructivepulmonarydisease (COPD). Downhill walking induces CMF with lower dyspnoea and fatigue than level walking. This study compared the effect of pulmonary rehabilitation (PR) comprising downhill walking training (DT) to PR comprising level walking
to the clinical effectiveness of the technology. Further information about how the evidence for this briefing was selected is available on request by contacting firstname.lastname@example.org. Published evidence Published evidence Three studies are summarised in this briefing, including 2 randomised controlled trials and 1 observational study. In total, there were 167 people with chronicobstructivepulmonarydisease (COPD) in these studies. The clinical evidence and its strengths and limitations is summarised (...) myCOPD for self-management of chronicobstructivepulmonarydisease myCOPD for self-management of chronicobstructivepulmonarydisease Medtech innovation briefing Published: 1 April 2020 www.nice.org.uk/guidance/mib214 pathways Summary Summary • The technology technology described in this briefing is myCOPD. It helps people with chronicobstructivepulmonarydisease (COPD) to manage their symptoms and reduce the number of healthcare visits they need. It also helps the healthcare professionals
Proton pump inhibitors for chronicobstructivepulmonarydisease. Chronicobstructivepulmonarydisease (COPD) is a common and progressive disease characterised by chronic cough, airflowlimitation and recurrent exacerbations. Since COPD exacerbations are linked to rising mortality and reduced quality of life, the condition poses a substantial burden on individuals, society and the healthcare system. Effective management of COPD exacerbations that includes treatment of related conditions (...) COPD exacerbations, pneumonia and other serious adverse events. Secondary outcomes were quality of life, lung function test indices, acute respiratory infections and disease-specific adverse events. We extracted data on these outcome measures and entered into them into Review Manager software for analysis.The search identified 99 records, and we included one multicentre RCT that randomised 103 adults with COPD. The 12-month RCT compared an oral PPI (lansoprazole) and usual care versus usual care
ChronicObstructivePulmonaryDisease. Chronicobstructivepulmonarydisease (COPD) is characterized by persistent respiratory symptoms and progressive airflowobstruction. Tobacco smoking is the leading cause but not the only one. A postbronchodilator FEV1-FVC ratio less than 0.70 is required for a diagnosis of COPD. Inhaler therapy is the backbone of treatment and should be complemented by a multifaceted management strategy that includes counseling and pharmacotherapy for smoking cessation (...) , pulmonary rehabilitation, treatment of comorbidities, administration of influenza and pneumococcal immunizations, and prescription of long-term oxygen therapy in hypoxemic patients.
Inhaled Salbutamol Shortage – Mitigation Strategy for COPD CTS Guidance on Salbutamol Shortage - April 13, 2020 1 Inhaled Salbutamol Shortage – Mitigation Strategy for COPD April 13, 2020 Background 1) Health Canada and the pharmaceutical industry have identified that there was a three-fold increase in the demand for salbutamol inhalers in the first 3 weeks of March 2020. 2) This has resulted in a Tier 3 shortage, which by definition is “a situation when a manufacturer/importer is unable (...) to meet demand for the drug. A tier 3 shortage is a shortage with the greatest potential impact on the Canadian drug supply and healthcare systems by virtue of availability of alternate supplies, ingredients, or therapies.” 3) Restrictions have been put in place by wholesalers and distributors to limit the supply of salbutamol which means that most patients will receive only one salbutamol inhaler or a one month supply at a time . 4) It is possible that the surge in demand relates to individuals
: Item in Clipboard Baduanjin exercise for chronicobstructivepulmonarydisease: an updated systematic review and meta-analysis Ailing Cao et al. Clin Rehabil . 2020 Aug . Show details Clin Rehabil Actions . 2020 Aug;34(8):1004-1013. doi: 10.1177/0269215520926635. Epub 2020 Jun 10. Authors , , , Affiliation 1 Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. PMID: 32517512 DOI: Item (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions . 2020 Aug;34(8):1004-1013. doi: 10.1177/0269215520926635. Epub 2020 Jun 10. Baduanjin exercise for chronicobstructivepulmonarydisease: an updated systematic review and meta-analysis , , , Affiliations Expand Affiliation 1 Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. PMID: 32517512 DOI
. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020:2000547. 8. Lippi G, Henry BM. Chronicobstructivepulmonarydisease is associated with severe coronavirus disease 2019 (COVID-19). Respiratory Medicine. 2020. DOI: https://doi.org/10.1016/j.rmed.2020.105941 9. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223 (...) distancing in the workplace setting is difficult to implement. Until we fully understand the risks associated with SARS-CoV-2 infection in patients with chroniclungdisease we have placed a high value on limiting exposure based on prior experience with influenza. COPD Management – General Statement In the absence of direct or indirect data that use of current inhaled COPD therapies impacts the severity of SARS-CoV-2 infection, we recommend that maintenance and exacerbation management for COPD
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronicobstructivepulmonarydisease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but studies at two dose levels are lacking.In a 52-week, phase 3, randomized trial to evaluate the efficacy and safety of triple therapy at two dose levels (...) of inhaled glucocorticoid in patients with moderate-to-very-severe COPD and at least one exacerbation in the past year, we assigned patients in a 1:1:1:1 ratio to receive twice-daily inhaled doses of triple therapy (inhaled glucocorticoid [320 μg or 160 μg of budesonide], a LAMA [18 μg of glycopyrrolate], and a LABA [9.6 μg of formoterol]) or one of two dual therapies (18 μg of glycopyrrolate plus 9.6 μg of formoterol or 320 μg of budesonide plus 9.6 μg of formoterol). The primary end point
Home noninvasive positive-pressure ventilation reduces mortality and intubations in COPD with hypercapnia. Wilson ME, Dobler CC, Morrow AS, et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronicobstructivepulmonarydisease: a systematic review and meta-analysis. JAMA. 2020;323:455-65. 32016309.
Association of Dysanapsis With ChronicObstructivePulmonaryDisease Among Older Adults. Smoking is a major risk factor for chronicobstructivepulmonarydisease (COPD), yet much of COPD risk remains unexplained.To determine whether dysanapsis, a mismatch of airway tree caliber to lung size, assessed by computed tomography (CT), is associated with incident COPD among older adults and lung function decline in COPD.A retrospective cohort study of 2 community-based samples: the Multi-Ethnic Study (...) of Atherosclerosis (MESA) Lung Study, which involved 2531 participants (6 US sites, 2010-2018) and the Canadian Cohort of ObstructiveLungDisease (CanCOLD), which involved 1272 participants (9 Canadian sites, 2010-2018), and a case-control study of COPD: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), which involved 2726 participants (12 US sites, 2011-2016).Dysanapsis was quantified on CT as the geometric mean of airway lumen diameters measured at 19 standard anatomic locations
Should You Recommend Inhaled Corticosteroids for This Patient With ChronicObstructivePulmonaryDisease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Approximately 12 million adults in the United States receive a diagnosis of chronicobstructivepulmonarydisease (COPD) each year, and it is the fourth leading cause of death. Chronicobstructivepulmonarydisease refers to a group of diseases that cause airflowobstruction and a constellation of symptoms, including cough (...) , sputum production, and shortness of breath. The main risk factor for COPD is tobacco smoke, but other environmental exposures also may contribute. The GOLD (Global Initiative for ChronicObstructiveLungDisease) 2020 Report aims to provide a nonbiased review of the current evidence for the assessment, diagnosis, and treatment of patients with COPD. To date, no conclusive evidence exists that any existing medications for COPD modify mortality. The mainstay of treatment for COPD is inhaled
No Additional Therapy? Conclusions Summary of Recommendations In patients with chronicobstructivepulmonarydisease (COPD) who complain of dyspnea or exercise intolerance, we recommend long-acting b 2 -agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy (strong recommendation, moderate certainty evidence). In patients with COPD who complain of dyspnea or exercise intolerance despite dual therapy with LABA/LAMA, we suggest the use of triple therapy (...) advise against the use of maintenance oral corticosteroid therapy (conditional recommendation, low certainty evidence). In individuals with COPD who experience advanced refractory dyspnea despite otherwise optimal therapy, we suggest that opioid-based therapy be considered for dyspnea management, within a personalized shared decision- making approach (conditional recommendation, very low certainty evidence). Introduction The Global Initiative for ChronicObstructiveLungDisease 2019 report de?nes
Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. Meta-analyses have suggested that initiating pulmonary rehabilitation after an exacerbation of chronicobstructivepulmonarydisease (COPD) was associated with improved survival, although the number of patients studied was small and heterogeneity was high. Current guidelines recommend that patients enroll in pulmonary rehabilitation after hospital (...) discharge.To determine the association between the initiation of pulmonary rehabilitation within 90 days of hospital discharge and 1-year survival.This retrospective, inception cohort study used claims data from fee-for-service Medicare beneficiaries hospitalized for COPD in 2014, at 4446 acute care hospitals in the US. The final date of follow-up was December 31, 2015.Initiation of pulmonary rehabilitation within 90 days of hospital discharge.The primary outcome was all-cause mortality at 1 year. Time
Phosphodiesterase-4 inhibitors for chronicobstructivepulmonarydisease. Chronicobstructivepulmonarydisease (COPD) is associated with cough, sputum production or dyspnoea, and a reduction in lung function, quality of life, and life expectancy. Apart from smoking cessation, no other treatments that slow lung function decline are available. Roflumilast and cilomilast are oral phosphodiesterase-4 (PDE₄) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD (...) in the analyses for roflumilast (28 trials with 18,046 participants) or cilomilast (14 trials with 6457 participants) or tetomilast (1 trial with 84 participants), with a duration between six weeks and one year or longer. These trials included people across international study centres with moderate to very severe COPD (Global Initiative for ChronicObstructiveLungDisease (GOLD) grades II to IV), with mean age of 64 years. We judged risks of selection bias, performance bias, and attrition bias as low overall